Eribulin Approved for Liposarcoma, Improves SurvivalEribulin Approved for Liposarcoma, Improves Survival

Already approved for use in breast cancer, eribulin is the first drug to show an improved overall survival in patients with liposarcoma. News Alerts
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news